Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 350, Issue 5, pp 441–453

Molecular pharmacology of somatostatin receptors

Authors

  • Daniel Hoyer
    • Preclinical Research, 360/604Sandoz Pharma Ltd.
  • Hermann Lübbert
    • Preclinical Research, 360/604Sandoz Pharma Ltd.
  • Christian Bruns
    • Preclinical Research, 360/604Sandoz Pharma Ltd.
Invited Review

DOI: 10.1007/BF00173012

Cite this article as:
Hoyer, D., Lübbert, H. & Bruns, C. Naunyn-Schmiedeberg's Arch Pharmacol (1994) 350: 441. doi:10.1007/BF00173012

Abstract

The neuropeptide somatostatin (SRIF) is widely expressed in the brain and in the periphery in two main forms, SRIF-14 and SRIF-28. Similarly, the presence of SRIF receptors throughout the whole body has been reported. SRIF produces a variety of effects including modulation of hormone release (e.g. GH, glucagon, insulin), of neurotransmitter release (e.g. acetylcholine, dopamine, 5-HT), and its own release is modulated by many neurotransmitters. SRIF affects cognitive and behavioural processes, the endocrine system, the gastrointestinal tract and the cardiovascular system and also has tumor growth inhibiting effects. Initially, two classes of SRIF receptors have been proposed on the basis of biochemical and functional studies. However, the recent cloning of five putative SRIF receptor subtypes which belong to the G-protein coupled receptor superfamily suggests that SRIF mediates its various effects via a whole family of receptors. Here we review, in this new context, the molecular pharmacology of the SRIF receptor subtypes present in the brain and in the periphery, and address the question of nomenclature of SRIF receptors.

Key words

SomatostatinSRIFReceptor subtypesMolecular cloningSecond messengersPathologyNomenclature

Abbreviations

BIM-23003

c[Cys-Lys-Asn p-Cl-Phe-Phe-d-Trp-Lys-Thr-Phe Thr-Ser-Cys]

BIM-23014

d-Nal-c[Cys Tyr-d-Trp-Lys Val-Cys]-Thr-NH2

BIM-23023

d-Phe-c[Cys Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2

BIM-23027

c[N-Me-AlaTyr-d-Trp-Lys-Abu-Phe]

BIM-23030

c[MPA-Tyr-d-Trp-Lys-Val-Cys]-Phe-NH2

BIM-23049

d-Nal-Ala-Tyr-d-Trp-Lys-Val-Ala Thr-NH2

BIM-23052

d-Phe-Phe-Phe-d-Trp-Lys-Thr-Phe-Thr-NH2

BIM-23055

d-Phe-Phe-Tyr-d-Trp-Lys-Val-Phe-d-Phe-NH2

BIM-23056

d-Phe-Phe-Tyr-d-Trp-Lys-Val-Phe-d-Nal-NH2

BIM-23058

d-Phe-Phe-Tyr-d-Trp-Lys-Val-Phe-Thr-NH2

BIM-23059

d-Nal-c[Cys-Tyrd-Trp-Lys-Thr-Cys]-Thr-NH2

CGP 23996

c[Asu-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Tyr-Thr-Ser]

L-362,823

c[Aha-[Cys-Phe-DTrp-Lys-Thr-Cys]]

L-362,855

c[Aha-Phe-Trp-d-Trp-Lys-Thr-Phe]

L-362,862

c[Aha-Phe-p-Cl-Phe-DTrp-Lys-Thr-Phe]

L-363,301

c[Pro-Phe-d-Trp-Lys-Thr-Phe]

L-363,572

c[d-Ala-d-Phe-d-Trp-Lys-d-Thr-N-Me-d-Phe]

MK-678

c[N-Me-Ala-Tyr-d-Trp-Lys-Val-Phe]

SA

c[Aha-Phe-d-Trp-Lys-Thr(Bzl)]

SMS 201-995

d-Phe-c[Cys-Phe-d-Trp-Lys-Thr-Cys]-Thr-ol

Download to read the full article text

Copyright information

© Springer-Verlag 1994